Current status of the taxanes as adjuvant therapy for breast cancer.
Adjuvant chemotherapy for breast cancer reduces the risks of recurrence and death in many subsets of patients. The quest for better regimens, defined as both more effective and less toxic has led to numerous clinical trials testing the taxanes in the adjuvant setting. These trials are generally positive but do not clearly identify a single best or ideal regimen for all patients. This paper reviews the available data in this area of clinical research.
Hudis
Clifford
C
Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, MSKCC, 1275 York Avenue, New York, NY, USA. hudisc@mskcc.org
McArthur
Heather
H
Dang
Chau
C
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local; D043823:Taxoids / Q000008:administration & dosage*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D043823:Taxoids